Efficacy gap between phase II and subsequent phase III studies in oncology

AIMS: There is a trend for more flexibility in timing of evidence generation in relation to marketing authorization, including the option to complete phase III trials after authorization or not at all. This paper investigated the relation between phase II and III clinical trial efficacy in oncology....

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Br J Clin Pharmacol
Autors principals: Vreman, Rick A., Belitser, Svetlana V., Mota, Ana T.M., Hövels, Anke M., Goettsch, Wim G., Roes, Kit C.B., Leufkens, Hubert G.M., Mantel‐Teeuwisse, Aukje K.
Format: Artigo
Idioma:Inglês
Publicat: John Wiley and Sons Inc. 2020
Matèries:
Original Articles
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7318994/
https://ncbi.nlm.nih.gov/pubmed/32034790
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bcp.14237
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars